CN102204910B - Pharmaceutical composition of moxifloxacin hydrochloride, and preparation method thereof - Google Patents
Pharmaceutical composition of moxifloxacin hydrochloride, and preparation method thereof Download PDFInfo
- Publication number
- CN102204910B CN102204910B CN201110074385.2A CN201110074385A CN102204910B CN 102204910 B CN102204910 B CN 102204910B CN 201110074385 A CN201110074385 A CN 201110074385A CN 102204910 B CN102204910 B CN 102204910B
- Authority
- CN
- China
- Prior art keywords
- weight portions
- moxifloxacin hydrochloride
- preparation
- pharmaceutical composition
- hot melt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960005112 moxifloxacin hydrochloride Drugs 0.000 title claims abstract description 30
- IDIIJJHBXUESQI-DFIJPDEKSA-N moxifloxacin hydrochloride Chemical group Cl.COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 IDIIJJHBXUESQI-DFIJPDEKSA-N 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 15
- 239000012943 hotmelt Substances 0.000 claims abstract description 25
- 239000008187 granular material Substances 0.000 claims description 27
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 26
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- 239000012530 fluid Substances 0.000 claims description 16
- 238000007909 melt granulation Methods 0.000 claims description 16
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 12
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 12
- 238000004132 cross linking Methods 0.000 claims description 12
- 239000000377 silicon dioxide Substances 0.000 claims description 12
- 235000012239 silicon dioxide Nutrition 0.000 claims description 12
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 12
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 12
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 239000007888 film coating Substances 0.000 claims description 7
- 238000009501 film coating Methods 0.000 claims description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 abstract description 15
- 239000003795 chemical substances by application Substances 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 9
- 229940093429 polyethylene glycol 6000 Drugs 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 abstract description 4
- 239000002245 particle Substances 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 230000008018 melting Effects 0.000 abstract description 2
- 238000002844 melting Methods 0.000 abstract description 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 25
- 238000005550 wet granulation Methods 0.000 description 12
- 238000004090 dissolution Methods 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- -1 nonane-8-yl Chemical group 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000007613 slurry method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 101710183280 Topoisomerase Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 229950005770 hyprolose Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FGBGEKHVEJJJLT-LLVKDONJSA-N 1-cyclopropyl-7-[(3r)-3-ethylpyrrolidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical class C1[C@H](CC)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC FGBGEKHVEJJJLT-LLVKDONJSA-N 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- 206010055000 Bromhidrosis Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a pharmaceutical composition of moxifloxacin hydrochloride, and a preparation method thereof. The composition mainly comprises moxifloxacin hydrochloride, a melting agent polyethylene glycol 6000 and other excipients. The preparation method mainly comprises the steps of: preparing drug particles by a hot melt granulating technology, and then tabletting or encapsulating.
Description
[technical field]
The invention belongs to technical field of medicine, more specifically, the present invention relates to a kind of pharmaceutical composition that contains moxifloxacin hydrochloride and fusing agent, also relates to the preparation method of described pharmaceutical composition.
[background technology]
Moxifloxacin hydrochloride (Moxifloxacin Hydrochloride), its chemistry 1-cyclopropyl-7-(S by name, S-2,8-diazonium-bicyclo-[4.3.0] nonane-8-yl) the fluoro-8-of-6-methoxy-1,4-dihydro-4-oxygen-3-quinoline carboxylic acid hydrochloride, is the efficient Development of Fluoroquinolone Antibacterials of New-type wide-spectrum of German Bayer company research and development, and commodity are called " visiing multiple pleasure ", in JIUYUE, 1999 is gone on the market in Germany, and the same year, December obtained FDA approval listing in the U.S..That uses clinically at present is mainly tablet.
Moxifloxacin hydrochloride raw material is crystalline powder, and mobility and compressibility are all poor, and said preparation specification is larger, needs the adjuvant limited space of interpolation, is not suitable for dry powder direct tabletting, and preparation technology is wet method granule tabletting processed.Traditional wet granulation, need to consider the addition, particle drying time of adhesive, the factors such as time of sieving of granulating, the machine quantity of need of production is many, space is large, and because some factor need to dependence experience judge, therefore may cause unstable product quality, between batch, difference is large etc.And along with the prolongation of resting period, may cause in addition the problem such as slack-off of dissolution.
And dry method granule technique processed need to be used the special installations such as dry granulating machine; also need by compressing, pulverize, sieve, the process such as granulate just can complete; operating process is loaded down with trivial details, time-consuming; artificially increased cost; and after tabletting, easily there is " taking off lid " phenomenon; or tablet friability is defective, in the coating process of postorder, easily there is fragment, make tablet quality defective.
Hot melt granule method processed is the emerging a kind of granulation technique of Abroad in Recent Years.This technology is different from hot-melt extruded granulation technique, and the latter need to use the special and expensive equipment such as hot-melt extruded granulator, and hot melt granule method processed only needs fluid bed to realize, and fluid bed is the common equipment generally using in modern pharmaceutical factory.This technology is time saving and energy saving, and quickness and high efficiency adapts to the development in modern pharmaceutical field.
[summary of the invention]
[technical problem that will solve]
Object of the present invention, to overcome the potential risk that prior art is brought to product stability in wet granule compression tablet technique, a kind of technology of preparing-hot melt granulation technique of time saving and energy saving, quickness and high efficiency is proposed, the application of this technology has not only reduced the production cost of product, has also guaranteed the quality of product simultaneously.
[technical scheme]
The present invention is achieved through the following technical solutions.
The present invention relates to a kind of pharmaceutical composition of moxifloxacin hydrochloride, it is characterized in that it by effective ingredient moxifloxacin hydrochloride with comprise fusing agent and other pharmaceutically acceptable carrier form, and the tablet of making by hot melt granulation technique, wherein fusing agent used is polyethylene glycol 6000.
The invention provides a kind of method that adopts hot melt granulation technique to prepare moxifloxacin hydrochloride medicinal composition, adopt fluid bed heat to found grain.Preparation technology is easy for this technology, time saving and energy saving, uniform particles, and good fluidity, tablet hardness is better, and friability is lower, and dissolution is obviously better than wet granulation.
Moxifloxacin hydrochloride is wide spectrum and the 8-methoxy fluoroquinolone class antimicrobial drug with antibacterial activity.Moxifloxacin hydrochloride is to gram positive bacteria, gram-negative bacteria, and anaerobe, acid fast bacteria, and atypical microorganism is as mycoplasma, chlamydia and legionella have broad spectrum antibiotic activity.Antibacterial action mechanism is for disturbing II, IV topoisomerase.Topoisomerase is to control the key enzyme of DNA topological sum at DNA replication dna, in repairing and transcribing.Its killing curve shows, Moxifloxacin is the bactericidal activity with concentration dependent.We know, the medicine with concentration dependent, refer to be blood drug level in body, so the stripping of medicine is fast, can make the absorption of medicine fast, reach very soon blood drug level effectively, bring into play rapidly drug effect, and if dissolution is slack-off, absorb slack-off accordingly, onset is slack-off, even may can not reach effective concentration because of medicine elimination and metabolic problems, thereby curative effect is very poor.
Hot melt granulation technique is different from hot-melt extruded granulation technique, the latter need to use the special and expensive equipment such as hot-melt extruded granulator, and hot melt granule method processed only needs fluid bed to realize, its operation principle is the material in material trough, the abundant mixed melting of adjuvant, by constant pressure and flow device, be delivered to the second-rate bromhidrosis stream nozzle at refrigerating chamber top, the compressed air atomization being produced by air compressor in refrigerating chamber becomes small droplet, fully contact with the air through cryotherapy, the exchange of conducting heat, complete solidification process, product after partly solidified is deposited in the powder cup of hothouse bottom, the tail gas of discharging from atomization refrigeration chamber completes gas solid separation in cyclone separator, product is captured down and collects in powder cup, tail gas enters atmosphere by air-introduced machine.Fluid bed is the common equipment generally using in modern pharmaceutical factory.This technology is time saving and energy saving, and quickness and high efficiency adapts to the development in modern pharmaceutical field.
In compositions of the present invention, contain moxifloxacin hydrochloride, fusing agent polyethylene glycol 6000 and other be acceptable carrier pharmaceutically.
Wherein pharmaceutically acceptable carrier should refer to the conventional medicine carrier in pharmaceutical field, such as disintegrating agent, lubricant etc., and disintegrating agent is as carboxymethyl starch sodium, hyprolose, polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose; Fluidizer is as silicon dioxide, gel silicon dioxide; Lubricant is as Pulvis Talci, calcium stearate, magnesium stearate, micropowder silica gel etc.
Preferably, described pharmaceutical composition is made by following raw material,
More preferably, described pharmaceutical composition is made by following raw material,
According to another kind of preferred implementation of the present invention, described preparation is tablet or capsule.
According to another kind of preferred implementation of the present invention, pharmaceutically acceptable carrier is that one or more are selected from the pharmaceutically carrier of normally used disintegrating agent, lubricant.
Described disintegrating agent is selected from carboxymethyl starch sodium, hyprolose, polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose.
Described lubricant is selected from Pulvis Talci, calcium stearate and magnesium, micropowder silica gel.
The invention still further relates to the preparation method of described pharmaceutical composition.The method step is as follows: moxifloxacin hydrochloride, polyethylene glycol 6000, disintegrating agent, fluidizer is put in fluid bed, carries out hot melt granulation.
The granule that the present invention further can obtain hot melt granulation is prepared into pharmaceutical preparation with galenic pharmacy routine techniques, as tablet, and capsule.And the moxifloxacin hydrochloride that the preparation of each unit contains 250mg, 500mg or 1000mg.
Therefore the preferred preparation method of the present invention is as follows:
Moxifloxacin hydrochloride, polyethylene glycol 6000, cross-linking sodium carboxymethyl cellulose and silicon dioxide are put in fluid bed, carry out hot melt granulation.
Particularly preferred preparation method is as follows: the moxifloxacin hydrochloride, 4-6 weight portion cross-linking sodium carboxymethyl cellulose, 40-60 weight portion polyethylene glycol 6000 and the 10 weight portion silicon dioxide that take 1000 weight portions are put in fluid bed, air intake frequency 30-40Hz, temperature of charge are set are the parameter such as 55-75 ℃ and carry out hot melt granulation, by adding magnesium stearate after the granule granulate making, mix, tabletting, film coating.
The present invention preferably fills a prescription and obtains through screening, is particularly conducive to commercial production.
In the present invention, the method and apparatus generally using that the those of ordinary skill in employing pharmaceutical technology field is known, the granule obtaining can be made to tablet with the combination of acceptable carrier pharmaceutically, these carriers that use or excipient are all easily to determine for the those of ordinary skill in pharmaceutical technology field, are also apparent.
[beneficial effect]
The present invention has following beneficial effect: the present invention adopts hot melt method of granulating pharmaceutical compositions, and its advantage is, compared to the prior art, preparation technology is easy, time saving and energy saving, uniform particles, good fluidity, the tablet hardness of compacting is better, friability is lower, also there will not be fragment in coating process, easily controls, this tablet stability is good simultaneously, and in accelerated stability test, dissolution and wet granulation relatively have a clear superiority in simultaneously.See accompanying drawing and subordinate list.
[accompanying drawing explanation]
Fig. 1 embodiment 1-4 and Dissolution of Tablet comparison wet granulation compacting
Through accelerated test, after 6 months, condition determination is: slurry method, 900ml water, 50rpm, 37 ℃.The Dissolution of Tablet of the visible wet granulation of result is considerably slower than the tablet that embodiment obtains.The Dissolution of Tablet comparison of the product of Fig. 2 embodiment and wet granulation compacting
Condition determination is: slurry method, 0.1NHCl, 50rpm, 37 ℃.Through accelerated test, after 6 months, the product dissolution of the visible wet granulation of result is slower than embodiment.
[specific embodiment]
Further illustrate by the following examples the present invention, but not as limitation of the present invention.
embodiment 1:
The PEG-4000 and the 10 weight portion silicon dioxide that take moxifloxacin hydrochloride 1000 weight portions, cross-linking sodium carboxymethyl cellulose 10 weight portions, 200 weight portions are put in fluid bed, it is that 30Hz, temperature of charge are 75 ℃ that air intake frequency is set, carry out hot melt granulation, by the granule making with in the rearmounted mixers of 18 mesh sieve granulate, add 1 weight portion magnesium stearate to mix 5 minutes, be pressed into 1000, then use
film coating.
embodiment 2:
Taking moxifloxacin hydrochloride 1000 weight portions, cross-linking sodium carboxymethyl cellulose 1 weight portion, 10 weight portion PEG-4000s and silicon dioxide 2 weight portions puts in fluid bed, it is that 40Hz, temperature of charge are 65 ℃ that air intake frequency is set, carry out hot melt granulation, by the granule making with in the rearmounted mixers of 18 mesh sieve granulate, add magnesium stearate 0.5 weight portion to mix 5 minutes, be pressed into 1000, then use
film coating.
embodiment 3:
Taking moxifloxacin hydrochloride 1000 weight portions, cross-linking sodium carboxymethyl cellulose 5 weight portions, PEG-4000 100 weight portions and silicon dioxide 5 weight portions puts in fluid bed, it is that 30Hz, temperature of charge are 55 ℃ that air intake frequency is set, carry out hot melt granulation, by the granule making with in the rearmounted mixers of 18 mesh sieve granulate, add magnesium stearate 0.1 weight portion to mix 5 minutes, be pressed into 1000, then use
film coating.
embodiment 4:
Taking moxifloxacin hydrochloride 1000 weight portions, cross-linking sodium carboxymethyl cellulose 7 weight portions, PEG-4000 50 weight portions and silicon dioxide 7 weight portions puts in fluid bed, it is that 40Hz, temperature of charge are 65 ℃ that air intake frequency is set, carry out hot melt granulation, by the granule making with in the rearmounted mixers of 18 mesh sieve granulate, add magnesium stearate 0.5 weight portion to mix 5 minutes, pack 1000 capsules into.
Below by data, further illustrate the advantage of pharmaceutical composition of the present invention.
The comparison of table 1 embodiment of the present invention and dry granulation technology result
As seen from the above table, from the character aspect comparison of operating time and labor intensity etc. and product intermediate, the present invention has obvious advantage than dry granulation technology and wet granulation technique.
Table 2 embodiment of the present invention and wet granulation technique are placed the comparison of stripping result after 6 months
Condition determination is: slurry method, 900ml water, 50rpm, 37 ℃.
As seen from the above table, from wet granulation product and accelerated test of the present invention result comparison in 6 months, the dissolution of wet granulation is considerably slower than the present invention, and the present invention and relatively there is no significant difference for 0 month.The present invention has obvious advantage in product quality than wet granulation technique.
Claims (4)
1. a preparation method for the pharmaceutical composition of moxifloxacin hydrochloride, is characterized in that, step is as follows:
The PEG-4000 and the 10 weight portion silicon dioxide that take moxifloxacin hydrochloride 1000 weight portions, cross-linking sodium carboxymethyl cellulose 10 weight portions, 200 weight portions are put in fluid bed, it is that 30Hz, temperature of charge are 75 ℃ that air intake frequency is set, carry out hot melt granulation, by the granule making with in the rearmounted mixers of 18 mesh sieve granulate, add 1 weight portion magnesium stearate to mix 5 minutes, be pressed into 1000, then use Opadry film coating.
2. a preparation method for the pharmaceutical composition of moxifloxacin hydrochloride, is characterized in that, step is as follows:
Taking moxifloxacin hydrochloride 1000 weight portions, cross-linking sodium carboxymethyl cellulose 1 weight portion, 10 weight portion PEG-4000s and silicon dioxide 2 weight portions puts in fluid bed, it is that 40Hz, temperature of charge are 65 ℃ that air intake frequency is set, carry out hot melt granulation, by the granule making with in the rearmounted mixers of 18 mesh sieve granulate, add magnesium stearate 0.5 weight portion to mix 5 minutes, be pressed into 1000, then use Opadry film coating.
3. a preparation method for the pharmaceutical composition of moxifloxacin hydrochloride, is characterized in that, step is as follows:
Taking moxifloxacin hydrochloride 1000 weight portions, cross-linking sodium carboxymethyl cellulose 5 weight portions, PEG-4000 100 weight portions and silicon dioxide 5 weight portions puts in fluid bed, it is that 30Hz, temperature of charge are 55 ℃ that air intake frequency is set, carry out hot melt granulation, by the granule making with in the rearmounted mixers of 18 mesh sieve granulate, add magnesium stearate 0.1 weight portion to mix 5 minutes, be pressed into 1000, then use Opadry film coating.
4. a preparation method for the pharmaceutical composition of moxifloxacin hydrochloride, is characterized in that, step is as follows:
Taking moxifloxacin hydrochloride 1000 weight portions, cross-linking sodium carboxymethyl cellulose 7 weight portions, PEG-4000 50 weight portions and silicon dioxide 7 weight portions puts in fluid bed, it is that 40Hz, temperature of charge are 65 ℃ that air intake frequency is set, carry out hot melt granulation, by the granule making with in the rearmounted mixers of 18 mesh sieve granulate, add magnesium stearate 0.5 weight portion to mix 5 minutes, pack 1000 capsules into.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110074385.2A CN102204910B (en) | 2011-03-25 | 2011-03-25 | Pharmaceutical composition of moxifloxacin hydrochloride, and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110074385.2A CN102204910B (en) | 2011-03-25 | 2011-03-25 | Pharmaceutical composition of moxifloxacin hydrochloride, and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102204910A CN102204910A (en) | 2011-10-05 |
| CN102204910B true CN102204910B (en) | 2014-10-29 |
Family
ID=44694155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110074385.2A Active CN102204910B (en) | 2011-03-25 | 2011-03-25 | Pharmaceutical composition of moxifloxacin hydrochloride, and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102204910B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1106900A2 (en) * | 2011-12-26 | 2013-11-05 | Ems Sa | SOLID PHARMACEUTICAL COMPOSITION UNDERSTANDING ANTIBOTH FAMILY OF QUINOLONES AND THE PROCESS OF OBTAINING THEM |
| CN108371655A (en) * | 2018-03-29 | 2018-08-07 | 重庆华邦制药有限公司 | Include the solid drugs and preparation method thereof of razaxaban |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1762357A (en) * | 2005-09-21 | 2006-04-26 | 深圳市天一时科技开发有限公司 | Oral medicinal formulation of moxifloxacin and its preparation method |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101732233B (en) * | 2009-11-19 | 2011-07-27 | 浙江工业大学 | Method for preparing solid dispersion |
-
2011
- 2011-03-25 CN CN201110074385.2A patent/CN102204910B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1762357A (en) * | 2005-09-21 | 2006-04-26 | 深圳市天一时科技开发有限公司 | Oral medicinal formulation of moxifloxacin and its preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102204910A (en) | 2011-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102204911B (en) | Moxifloxacin hydrochloride pharmaceutical composition and its preparation method | |
| CN101147746A (en) | Processing method of Chinese medicinal material wall-broken powder | |
| CN103191069A (en) | Rapid disintegration tabella and chill-pressing method thereof | |
| CN101780085B (en) | Cefprozil medicinal composition | |
| CN1274298C (en) | Disintegrants for deodoring effectively and their preparation | |
| CN104146975A (en) | Montelukast sodium chewable tablet, preparation method and determination method of dissolution rate | |
| CN103655639A (en) | Spirulina tablet, and preparation method thereof | |
| CN106265581B (en) | Tranexamic acid tablet and preparation method thereof | |
| CN102204910B (en) | Pharmaceutical composition of moxifloxacin hydrochloride, and preparation method thereof | |
| CN103610658A (en) | Immunomodulator slow-release preparation and preparation method thereof | |
| CN102188420B (en) | Levetiracetam medicinal composition and preparation method thereof | |
| CN102894251A (en) | Multi-taste inulin composite tablet | |
| CN101703448A (en) | Direct compression process for cefuroxime axetil dispersible tablets | |
| CN109512792A (en) | A kind of process of the Genpril of granulation production twice | |
| CN103961351A (en) | Preparation method of amoxicillin and clavulanate potassium tablets | |
| CN117443284A (en) | Method for improving compression agglomeration and moisture absorption wall adhesion of coenzyme Q10 raw powder | |
| CN107468655B (en) | Lentinan particles and preparation method thereof | |
| CN102379855A (en) | Glimepiride dispersible tablet and preparation method thereof | |
| CN106924192B (en) | Traditional Chinese medicine granules and preparation method thereof | |
| CN103479589A (en) | Cefpodoxime proxetil dispersible tablet and preparation method thereof | |
| CN102949401A (en) | Composition of acetaminophen, acetylsalicylic acid and caffeine and preparation process thereof | |
| CN104523627B (en) | Clopidogrel hydrogen sulfate tablet medicine composition and preparation method thereof | |
| CN102949369B (en) | Preparation method of gemifloxacin mesylate medicinal composition | |
| CN103315972B (en) | A kind of Moxifloxacin hydrochloride tablet and preparation method thereof | |
| CN102697754B (en) | Irbesartan capsules and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 100021 Beijing city Chaoyang District West business center boziwan Jinhai rich 402 (A) 21 storey building Applicant after: China Resources Saike Pharmaceutical Co., Ltd. Address before: 100021 Beijing city Chaoyang District West business center boziwan Jinhai rich 402 (A) 21 storey building Applicant before: Saike Pharmaceutical Co., Ltd., Beijing |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: SAIKE PHARMACEUTICAL CO., LTD., BEIJING TO: CHINA RESOURCES SAIKE PHARMACEUTICAL CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |